The purpose of this study is to assess the clinical efficacy of the LCPT En-varsus \[Life-Cycle Pharma Tacrolimus\] initiated in de novo (Day 0 of transplantation) using the Biopsy Proven Acute Re-jection and iBox (full and abbreviated algo-rithms).
Kidney recipients aged 18 years and older.
Kidney recipients were transplanted from living or deceased donors
Patients receiving Envarsus® [Life-Cycle Pharma Tacrolimus] within 24 hours of kidney transplantation in a once-daily formulation at the discretion of the investiga-tor and in compliance with the summary of product characteristics.
Patients are willing to participate in the study and do not oppose the use of their data.
Contraindications to the use of Life-Cycle Pharma Tacrolimus (Envarsus®).
Pre-transplant desensitization.
ABO is incompatible with a living donor.
Combined transplant (e.g. kidney-heart transplant, kidney-liver transplant).